STS and prostate carcinoma: Indeed, there is growing compelling evidence that castration-resistant prostate cancers treated with the 17β-hydroxylase inhibitors abiraterone or enzalutamide, may utilise adrenal androgens, particularly DHEA-S, through STS action [54].